XML 74 R53.htm IDEA: XBRL DOCUMENT v3.6.0.2
ALLIANCES (AstraZeneca) (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Alliances Statement [Line Items]                            
Number of agreements in alliance 3                 3        
The percentage of capital expenditures to be reimbursed by AstraZeneca                         50.00%  
Net product sales                   $ 17,702 $ 14,045 $ 11,660    
Alliance revenues                   1,725 2,515 4,219    
Total Revenues $ 5,243 $ 4,922 $ 4,871 $ 4,391 $ 4,287 $ 4,069 $ 4,163 $ 4,041   19,427 16,560 15,879    
Royalties                   (618) (293) (192)    
Transitional services                   (238) (122) (170)    
Divestiture gain                   (564) (194) (564)    
Deferred income - Cash flow                   (64) 218 613    
Divestiture and other proceeds                   1,317 697 3,565    
AstraZeneca [Member]                            
Alliances Statement [Line Items]                            
Proceeds received at closing for sale of business                       2,700    
Total contingent regulatory and sales based milestone payments                       1,400    
Contingent approval milestones                       800    
Total contingent sales based milestones                       600    
Contingent payments related to transfer of certain assets and businesses                       225    
Business sale total consideration received                     179 3,800    
Contingent regulatory milestone consideration received                       700    
Portion of proceeds allocated to the sale of business                       3,300    
Portion of proceeds allocated to undelivered elements                       492    
Total earned royalties                       235    
Allocation of goodwill to disposal group                       600    
Reversal of deferred tax liabilities attributed to inside tax basis of disposal group                       821    
Net product sales                     14 160    
Alliance revenues                   129 182 135    
Total Revenues                   129 196 295    
Cost of products sold - Profit sharing                     1 79    
Cost reimbursements                       (33)    
Other (income)/expense - Amortization of deferred income                   (113) (105) (80)    
Royalties                   (227) (215) (192)    
Transitional services                   (7) (12) (90)    
Divestiture gain           $ 79     $ 292   (82) (536)    
Deferred income - Cash flow                   19 34 315    
Divestiture and other proceeds                   216 374 $ 3,495    
Deferred income 38       $ 144         38 $ 144      
AstraZeneca [Member] | Amylin Acquisition [Member]                            
Alliances Statement [Line Items]                            
Payment made by an alliance partner to enter into an alliance agreement                           $ 3,600
Payment made by an alliance partner to establish equal governance rights over certain key strategic and financial decisions regarding the alliance                         $ 135  
Useful life of property, plant and equipment                         15 years  
AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                            
Alliances Statement [Line Items]                            
Royalty rate sales threshold - Minimum 500                 500        
Royalty rate sales threshold - Maximum $ 500                 $ 500        
AstraZeneca [Member] | Onglyza Kombiglyze [Member] | Upfront, milestone and other licensing payments [Member]                            
Alliances Statement [Line Items]                            
Total upfront, milestone and other licensing payments received to date                         $ 300  
AstraZeneca [Member] | Amylin Related Products [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales                   2.00% 2.00%      
Royalty rate on net sales - 2017                   5.00%        
Royalty rate on net sales - 2018                   10.00%        
Royalty rate on net sales - 2019                   12.00%        
Percentage of potential future royalties transferred                   70.00%        
AstraZeneca [Member] | Farxiga [Member] | Upfront, milestone and other licensing payments [Member]                            
Alliances Statement [Line Items]                            
Total upfront, milestone and other licensing payments received to date                         $ 250  
AstraZeneca [Member] | Bydureon [Member]                            
Alliances Statement [Line Items]                            
Useful life of intangible asset                         13 years  
AstraZeneca [Member] | Byetta [Member]                            
Alliances Statement [Line Items]                            
Useful life of intangible asset                         7 years  
AstraZeneca [Member] | Symlin [Member]                            
Alliances Statement [Line Items]                            
Useful life of intangible asset                         9 years  
AstraZeneca [Member] | Myalept [Member]                            
Alliances Statement [Line Items]                            
Useful life of intangible asset                         12 years  
CPPIB [Member]                            
Alliances Statement [Line Items]                            
Royalties                   $ 134        
Maximum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales                   27.00% 35.00% 44.00%    
Royalty rate on net sales - 2017                   12.00%        
Royalty rate on net sales - 2018                   20.00%        
Royalty rate on net sales - 2019                   22.00%        
Royalty rate on net sales - future periods                   25.00%        
Maximum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales - future periods                   12.00%        
Minimum [Member] | AstraZeneca [Member] | Onglyza, Kombiglyze and Forxiga [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales                   9.00% 7.00% 3.00%    
Royalty rate on net sales - 2017                   12.00%        
Royalty rate on net sales - 2018                   20.00%        
Royalty rate on net sales - 2019                   22.00%        
Royalty rate on net sales - future periods                   14.00%        
Minimum [Member] | AstraZeneca [Member] | Amylin Related Products [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales - future periods                   5.00%